Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Farmaceutica RemediaBSE:RMAH +0.23%58 Gross Margin % is 8.37% as of Mar. 2026, which is 10% below its 10-year median of 9.28. GuruFocus rates BSE:RMAH with a GF Score™ of 58/100 and a GF Value™ of lei0.79 (Fairly Valued). The stock has 8 warning signs investors should review. Among 116 Medical Distribution companies, Farmaceutica Remedia ranks worse than 81.9% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Farmaceutica Remedia had a gross margin of 8.37% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Farmaceutica Remedia Gross Margin % Related Terms
Farmaceutica Remedia Gross Margin % Historical Data
* Premium members only.
The historical data trend for Farmaceutica Remedia's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSE:RMAH vs MCK, CAH, COR: Gross Margin % Comparison
For the Medical Distribution subindustry, Farmaceutica Remedia's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmaceutica Remedia Gross Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Farmaceutica Remedia's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Farmaceutica Remedia (BSE:RMAH) has a Gross Margin % of 8.37% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Farmaceutica Remedia and its competitors. This is 10% below median its historical median of 9.28. Over the past decade, Farmaceutica Remedia's Gross Margin % has ranged from 7.72 to 12.55. According to the industry distribution chart, Farmaceutica Remedia ranks #95 out of 116 companies in the Medical Distribution industry, placing it in the top 81.9%.
Is Farmaceutica Remedia's Gross Margin % too high?
Farmaceutica Remedia's current Gross Margin % of 8.37% is 10% below median its 10-year median of 9.28. Over the past 10 years, this metric has ranged from a low of 7.72 to a high of 12.55. The Medical Distribution industry median Gross Margin % is 14.90. Farmaceutica Remedia's value of 8.37% is 43.8% below this industry median. Based on the distribution chart, Farmaceutica Remedia ranks #95 out of 116 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Farmaceutica Remedia has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Farmaceutica Remedia's Gross Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Farmaceutica Remedia ranks #95 out of 116 companies for Gross Margin %. This places Farmaceutica Remedia in the lower half of its industry. The industry median Gross Margin % is 14.90. Farmaceutica Remedia's value of 8.37% is 43.8% below this benchmark. Historically, Farmaceutica Remedia's own Gross Margin % has ranged from 7.72 to 12.55 over the past decade. While the company's 10-year median is 9.28 vs. the industry median of 14.90, Farmaceutica Remedia has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Distribution company?
The median Gross Margin % among Medical Distribution companies is 14.90, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Farmaceutica Remedia's current Gross Margin % of 8.37% is 43.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Farmaceutica Remedia and its competitors. For the Medical Distribution industry, the median Gross Margin % is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farmaceutica Remedia's current Gross Margin % is 8.37%, which is 10% below median its own 10-year median of 9.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmaceutica Remedia stock overvalued right now?
Based on GuruFocus' analysis, Farmaceutica Remedia (BSE:RMAH) is currently considered Fairly Valued. The stock's GF Value™ is lei0.79, compared to a current price of lei0.87 — trading 10.1% above its estimated fair value. The current Gross Margin % is 8.37%, which is 10% below median its 10-year median of 9.28 and 43.8% below the Medical Distribution industry median of 14.90. Farmaceutica Remedia's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Farmaceutica Remedia (BSE:RMAH), the current Gross Margin % is 8.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmaceutica Remedia (BSE:RMAH) Overvalued in 2026?
Based on GuruFocus' analysis, Farmaceutica Remedia stock appears to be overvalued.
The current stock price of lei0.87 is trading 10.1% above its estimated GF Value™ of lei0.79.
GuruFocus considers Farmaceutica Remedia to be Fairly Valued.
Key valuation signals for BSE:RMAH:
Gross Margin %: 8.37% (10% below median its 10-year median of 9.28)
GF Value™: lei0.79 vs. price of lei0.87 (10.1% above fair value)
Industry Position: 43.8% below the Medical Distribution median (#95 of 116)
No single metric tells the full story. See the BSE:RMAH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
58GF Score
Get the complete analysis for BSE:RMAH
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:RMAH has been successfully added to your 
